Last reviewed · How we verify

Menopur® Inj. — Competitive Intelligence Brief

Menopur® Inj. (Menopur® Inj.) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gonadotropin. Area: Reproductive Medicine / Fertility.

marketed Gonadotropin FSH receptor and LH receptor Reproductive Medicine / Fertility Small molecule Live · refreshed every 30 min

Target snapshot

Menopur® Inj. (Menopur® Inj.) — LG Life Sciences. Menopur is a purified preparation of human menopausal gonadotropins (hMG) containing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) that stimulates ovarian follicle development and hormone production in women undergoing fertility treatment.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Menopur® Inj. TARGET Menopur® Inj. LG Life Sciences marketed Gonadotropin FSH receptor and LH receptor
COS with GnRH antagonists and HP-HMG COS with GnRH antagonists and HP-HMG Instituto Valenciano de Infertilidad, IVI VALENCIA marketed Gonadotropin protocol / Assisted reproductive technology regimen GnRH receptor (antagonism); FSH receptor and LH receptor (agonism via exogenous gonadotropins)
rhFSH+rhLH rhFSH+rhLH Fundación Santiago Dexeus Font marketed Gonadotropin FSH receptor and LH receptor
Follitropin alfa and lutropin alfa Follitropin alfa and lutropin alfa D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology marketed Gonadotropin FSH receptor and LH receptor
DUOSTIM DUOSTIM Centre Hospitalier Intercommunal Creteil phase 3 Gonadotropin combination therapy FSH receptor and LH receptor
Orgovyx relugolix MYOVANT SCIENCES marketed Gonadotropin Releasing Hormone Receptor Antagonist [EPC] Gonadotropin-releasing hormone receptor 2020-01-01
Orilissa ELAGOLIX AbbVie marketed Gonadotropin Releasing Hormone Receptor Antagonist Gonadotropin-releasing hormone receptor 2018-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Gonadotropin class)

  1. Instituto Valenciano de Infertilidad, IVI VALENCIA · 4 drugs in this class
  2. Sisli Hamidiye Etfal Training and Research Hospital · 3 drugs in this class
  3. Organon and Co · 3 drugs in this class
  4. Fundación Santiago Dexeus Font · 3 drugs in this class
  5. Merck KGaA · 2 drugs in this class
  6. Nina la Cour Freiesleben · 2 drugs in this class
  7. IVI Madrid · 2 drugs in this class
  8. Dunamenti REK Istenhegyi IVF Center · 1 drug in this class
  9. D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology · 1 drug in this class
  10. Azienda USL Modena · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Menopur® Inj. — Competitive Intelligence Brief. https://druglandscape.com/ci/menopur-inj. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing